Yousra Iftequar

Dr. Yousra Iftequar

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2026 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
HWHakim Ullah Wazir
Hakim Ullah Wazir
AKAbdul Muqeet Khuram
Abdul Muqeet Khuram
IRI M Khalid Reza
I M Khalid Reza
HAHafsa Ajmal
Hafsa Ajmal
HPHafsa Parveen
Hafsa Parveen
USUssama Shafaqat
Ussama Shafaqat
Background: Growing antibiotic resistance and the limited availability of key components in standard Helicobacter pylori treatments have driven the search for effective alternatives. Minocycline, with its broad-spectrum activity and favorable pharmacokinetics, has emerged as a promising substitute. This meta-analysis compares the safety and efficacy of minocycline-containing bismuth quadruple therapy (MBQT) to conventional first-line BQT regimens, incorporating data from the recent study by Lin et al. Methods: The inclusion criteria were randomized controlled trials (RCTs) with a target population of both treatment-naïve and previously treated patients diagnosed with Helicobacter pylori (H. pylori) infection. The intervention received by eligible patients was a minocycline–bismuth quadruple therapy (MBQT) regimen containing bismuth, minocycline, proton pump inhibitors (PPI), and any additional antibiotic with a minimum period of 2 weeks of administration. We excluded study designs other than RCT and clinical trials that include patients without confirmed H. pylori infection, animal populations, in vitro experiments, and reports of other outcomes that did not include a minimum intervention duration of 2 weeks. A comprehensive literature search was conducted on PubMed, EMBASE, Cochrane Library, and ScienceDirect from inception to 20 May 2025. After screening via Rayyan, data were extracted on an Excel spreadsheet. Quality was assessed using the Cochrane RoB 2.0 tool. Eligible randomized controlled trials (RCTs) were included and analyzed using RevMan 5.4. Outcomes assessed were intention-to-treat and per-protocol eradication rates. Adverse effects were compared among therapies. A random-effects model was used; an I2 < 50% and p-value < 0.05 indicated homogeneity and significant results respectively. Results: Five RCTs with 7 interventions involving 2812 patients were included. The pooled odds ratio (OR) for MBQT in intention-to-treat (ITT) analysis was 1.25 (95% CI: 0.96–1.61), showing a non-significant trend. No heterogeneity was detected (I2 = 0.0%). In the modified ITT (mITT) analysis (2 studies), MBQT showed higher eradication (OR: 1.70, 95% CI: 0.00–1042.90), but wide CI and high heterogeneity (I2 = 70.7%) limited interpretation. All studies were included in the per-protocol (PP) analysis, which showed a statistically significant improvement with MBQT (OR: 1.67, 95% CI: 1.14–2.45) and low heterogeneity (I2 = 5.2%), suggesting consistent results. Although not statistically significant, MBQT was associated with a slightly lower rate of adverse events compared to standard therapy (OR: 0.81, 95% CI: 0.59–1.12). I2 = 50.6% showed moderate heterogeneity in safety outcomes. Discussion: the number of included RCTs was modest, with only five studies meeting eligibility criteria, and only two contributing to the modified intention-to-treat analysis. The risk-of-bias assessment showed variation in methodological quality across the included studies. Several studies exhibited high risk judgments in critical domains. particularly randomization, deviations from intervention, and selective reporting. Patients who completed the treatment benefited more from MBQT, which also had a comparable safety profile to conventional BQT regimens. In the treatment of H. pylori infection, MBQT may be considered a safe alternative for first-line treatment.

28 July 2025
Verified
Book Chapter
Open access
PDF file
MAMansi Agrawal
Mansi Agrawal
BBBraahmani Bobba
Braahmani Bobba
YIYousra Iftequar
Yousra Iftequar
MLMacharla Lekhana
Macharla Lekhana
AGAditya Samitinjay Gade
Aditya Samitinjay Gade
RBRakesh Biswas
Rakesh Biswas
This chapter is the succeeding section to Chapter 2 based on Participatory Medicine Models and Learning. The roots of telemedicine grew decades ago and is revolutionizing healthcare. But why do we need telemedicine and what exactly is telemedicine? The following chapter answers these questions with in depth explanation of one of our pioneering telemedicine models, Patient Journey Records (PaJR). The concept behind PaJR, utilization of its data and its workflow along with real-world scenarios are discussed here. We are growing forward with this journey with new reformations every day. PaJR is not only a tool making data collection and follow-up process easier, it’s also an effective learning tool for all the learners involved in the patient’s journey. In a brief sentence, PaJR is akin to the patient’s personal journal with interactive and professional feedback from the health personnel on a regular basis making telemedicine available via basic digital tools equitable.

17 June 2026 in Internal and Emergency Medicine
Verified
Journal Article
Open access
YIYousra Iftequar
Yousra Iftequar
PBPrakhar Bajpai
Prakhar Bajpai
RDRajvi Dav
Rajvi Dav
KHKaza Sri Harshitha
Kaza Sri Harshitha
CCChandan C
Chandan C
RCRishi Chowdhary
Rishi Chowdhary
Introduction: Irritable bowel syndrome (IBS) is a prevalent functional disorder, comprising constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), and mixed (IBS-M) subtypes. Emerging research has shown that the pathophysiological influences of SIBO are significant in IBS, particularly in IBS-D. Variations in therapeutic responsiveness and diagnostic paradigms across IBS subtypes necessitate a tailored, subtype-specific management framework. Methods: A review of identification strategies, SIBO subtype-specific prevalence, and treatment outcomes was supplemented through controlled randomized trials and observational studies. The treatment outcomes were evaluated in relation to SIBO and within the frameworks of rifaximin, neomycin, probiotics, and dietary modulation. Results: The prevalence of SIBO is notably greater in IBS patients, particularly in those with IBS-D, with figures estimating ranges from 30 to 60% depending upon the diagnostic methods and cutoff thresholds. Though limited in its sensitivity and standardization, breath testing, particularly glucose hydrogen/methane tests, remains the most widely accessible diagnostic technique. Methane-predominant SIBO in IBS-C does respond better to rifaximin–neomycin combinations, but rifaximin provides strong symptom relief in IBS-D. Significant gaps persist, however, with the absence of longitudinal outcome measurements and standardization of IBS diagnostic criteria. In order to improve the care for IBS patients, the strategies targeting precision medicine with microbiota profiling and algorithm-driven personalized therapies must be accorded priority. Conclusions: SIBO is increasingly recognized as a potential contributor in a subset of patients with IBS, with rifaximin being most beneficial for IBS-D, particularly when utilized in addition to dietary measures. IBS-C and IBS-M require individualized, multimodal therapy, and future studies should direct efforts toward subtype-specific, precision medicine treatments for improved long-term outcomes.